Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sung Gwe Ahn | - |
dc.contributor.author | Seok Jin Nam | - |
dc.contributor.author | Sei Hyun Ahn | - |
dc.contributor.author | Yongsik Jung | - |
dc.contributor.author | Heung Kyu Park | - |
dc.contributor.author | Soo Jung Lee | - |
dc.contributor.author | Sung Soo Kang | - |
dc.contributor.author | Wonshik Han | - |
dc.contributor.author | Kyong Hwa Park | - |
dc.contributor.author | Yong Lai Park | - |
dc.contributor.author | Jihyoun Lee | - |
dc.contributor.author | Hyun Jo Youn | - |
dc.contributor.author | Jun Hyun Kim | - |
dc.contributor.author | Youngbum Yoo | - |
dc.contributor.author | Jeong-Yoon Song | - |
dc.contributor.author | Byung Kyun Ko | - |
dc.contributor.author | Geumhee Gwak | - |
dc.contributor.author | Min Sung Chung | - |
dc.contributor.author | Sung Yong Kim | - |
dc.contributor.author | Seo Heon Cho | - |
dc.contributor.author | Doyil Kim | - |
dc.contributor.author | Myung-Chul Chang | - |
dc.contributor.author | Byung In Moon | - |
dc.contributor.author | Lee Su Kim | - |
dc.contributor.author | Sei Joong Kim | - |
dc.contributor.author | Min Ho Park | - |
dc.contributor.author | Tae Hyun Kim | - |
dc.contributor.author | Jihyoung Cho | - |
dc.contributor.author | Cheol Wan Lim | - |
dc.contributor.author | Young Tae Bae | - |
dc.contributor.author | Gyungyub Gong | - |
dc.contributor.author | Young Kyung Bae | - |
dc.contributor.author | Ahwon Lee | - |
dc.contributor.author | Joon Jeong | - |
dc.date.accessioned | 2021-05-14T00:40:04Z | - |
dc.date.available | 2021-05-14T00:40:04Z | - |
dc.date.created | 2021-04-29 | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 1738-6756 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81006 | - |
dc.description.abstract | Purpose: In this trial, we investigated the efficacy and safety of adjuvant letrozole for hormone receptor (HR)-positive breast cancer. Here, we report the clinical outcome in postmenopausal women with HR-positive breast cancer treated with adjuvant letrozole according to estrogen receptor (ER) expression levels. Methods: In this multi-institutional, open-label, observational study, postmenopausal patients with HR-positive breast cancer received adjuvant letrozole (2.5 mg/daily) for 5 years unless they experienced disease progression or unacceptable toxicity or withdrew their consent. The patients were stratified into the following 3 groups according to ER expression levels using a modified Allred score (AS): low, intermediate, and high (AS 3–4, 5–6, and 7–8, respectively). ER expression was centrally reviewed. The primary objective was the 5-year disease-free survival (DFS) rate. Results: Between April 25, 2010, and February 5, 2014, 440 patients were enrolled. With a median follow-up of 62.0 months, the 5-year DFS rate in all patients was 94.2% (95% confidence interval [CI], 91.8–96.6). The 5-year DFS and recurrence-free survival (RFS) rates did not differ according to ER expression; the 5-year DFS rates were 94.3% and 94.1%in the low-to-intermediate and high expression groups, respectively (p = 0.6), and the corresponding 5-year RFS rates were 95.7% and 95.4%, respectively (p = 0.7). Furthermore, 25 patients discontinued letrozole because of drug toxicity. Conclusion: Treatment with adjuvant letrozole showed very favorable treatment outcomes and good tolerability among Korean postmenopausal women with ER-positive breast cancer, independent of ER expression. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 한국유방암학회 | - |
dc.relation.isPartOf | Journal of Breast Cancer | - |
dc.title | Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006) | - |
dc.title.alternative | Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006) | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000645155800004 | - |
dc.identifier.doi | 10.4048/jbc.2021.24.e17 | - |
dc.identifier.bibliographicCitation | Journal of Breast Cancer, v.24, no.2, pp.164 - 174 | - |
dc.identifier.kciid | ART002708885 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85105580074 | - |
dc.citation.endPage | 174 | - |
dc.citation.startPage | 164 | - |
dc.citation.title | Journal of Breast Cancer | - |
dc.citation.volume | 24 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Heung Kyu Park | - |
dc.subject.keywordAuthor | Breast neoplasms | - |
dc.subject.keywordAuthor | Letrozole | - |
dc.subject.keywordAuthor | Postmenopause | - |
dc.subject.keywordAuthor | Receptors | - |
dc.subject.keywordAuthor | estrogen | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.